TOP TIERMARKET NEWSWIRE
News & sentiment

ENLIVEN THERAPEUTICS (ELVN) — News & AI sentiment

ENLIVEN THERAPEUTICS (ELVN) news roundup. 9 stories aggregated over the last 30 days. Average 30-day sentiment is 61.2/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 10 sales totalling $63.5M — net selling of $63.5M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
9
avg sentiment 61.2/100
Insider net (90d)
$63.5M
0 buys · 10 sells
Congress (90d)
0
0 buys · 0 sells

ELVN news in the last 24 hours, 7 days, 30 days and 90 days

How much ELVN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowELVN storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days961.2/100ELVN headlines →
Last 90 days2250.9/100ELVN headlines →

Latest stories on ELVN

Sep 3
Sep 3
Aug 31
Aug 18
Aug 18
William Blair initiates Enliven Therapeutics stock with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
Aug 18
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT
Investing.com Analyst Ratings61 · neutralanalyst
Aug 18
Aug 18
Aug 18
Aug 6
Guggenheim lowers Enliven Therapeutics stock price target to $78
Investing.com Analyst Ratings34 · bearishanalyst
Aug 6
Aug 5
Aug 5
Aug 5
Jul 10
Jun 27
Jun 27
Jun 24
Jun 22
Jun 15
Jun 15
Jun 15
Jun 13
Jun 12
Jun 12
Open ELVN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →